Simvastatin, a cholesterol-lowering drug, can suppress the HIF-1α/PPAR-γ/PKM2 axis via inhibiting PKM2-mediated glycolysis, leading to reduced proliferation and increased apoptosis in HCC cells and re-sensitizing HCC cells to sorafenib.62 This evidence concerns the gene HIF1A and hepatocellular carcinoma.